PATHWAY-2: spironolactone for resistant hypertension

Lancet. 2016 Apr 2;387(10026):1371-1372. doi: 10.1016/S0140-6736(16)30075-7.

Authors

Chrysoula Boutari¹, Konstantinos Stavropoulos¹, Konstantinos Imprialos¹, Micheal Doumas², Asterios Karagiannis¹

Affiliations

¹ 2nd Propedeutic Department of Internal Medicine, Aristotle University, Thessaloniki 54643, Greece.
² 2nd Propedeutic Department of Internal Medicine, Aristotle University, Thessaloniki 54643, Greece. Electronic address: [email protected].

PMID: 27115810
DOI: 10.1016/S0140-6736(16)30075-7

No abstract available

Publication types

Letter
Comment

MeSH terms

Adrenergic alpha-1 Receptor Antagonists / therapeutic use*
Adrenergic beta-1 Receptor Antagonists / therapeutic use*
Bisoprolol / therapeutic use*
Doxazosin / therapeutic use*
Female
Humans
Hypertension / drug therapy*
Male
Mineralocorticoid Receptor Antagonists / therapeutic use*
Spironolactone / therapeutic use*

Substances

Adrenergic alpha-1 Receptor Antagonists
Adrenergic beta-1 Receptor Antagonists
Mineralocorticoid Receptor Antagonists
Spironolactone
Doxazosin
Bisoprolol